Active Stocks
Fri Dec 08 2023 15:59:53
  1. Tata Steel share price
  2. 129.2 -0.62%
  1. HDFC Bank share price
  2. 1,653.1 1.38%
  1. State Bank Of India share price
  2. 614 0.35%
  1. NTPC share price
  2. 285.25 0.42%
  1. ITC share price
  2. 449.15 -1.95%
Business News/ Companies / Company Results/  JB Pharma’s revenue surges 30% in Q1, PAT declines
Back Back

JB Pharma’s revenue surges 30% in Q1, PAT declines

JB Pharma’s domestic formulations business grew at 34% in Q1, while international business revenue rose 28%

JB Pharma recorded robust revenue growth despite a challenging operating environment (Getty Images/iStockphoto)Premium
JB Pharma recorded robust revenue growth despite a challenging operating environment (Getty Images/iStockphoto)

New Delhi: JB Pharmaceuticals recorded a revenue of 785 crores in the quarter ended June, up 30% over the corresponding quarter of last year. Profit after tax, however, declined to 105 crore in Q1FY23 as compared to 119 crores on account of finance costs and acquisition of brands.

The Mumbai-based company’s operating Ebitda or earnings before interest, taxes, depreciation and amortization increased 16% to 190 crore.

“Our operating performance in FY23 started on a strong note. We continued the momentum in our domestic business, registering market beating growth and achieving a new milestone in quarterly run-rate revenue of over 400 crores. Integration of Sanzyme’s product range and Azmarda have progressed as per plan. We also completed the acquisition of a portfolio of paediatric brands which will enable us to offer a more comprehensive product basket to pediatricians, helping us to serve them better. International business also saw strong growth with a robust order pipeline and out-performance in the CMO segment," said Nikhil Chopra, CEO, JB Pharma.

The company recorded robust revenue growth despite a challenging operating environment, while the organic growth was pegged at around 20%, it said.

Domestic formulations business continued its strong performance, growing at 34% to 418 crores. International business revenues grew by 28% to 366 crores. All the three businesses --exports formulations, CMO and API business-- performed well in the quarter, the company said.

Milestone Alert!
Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.

Priyanka Sharma
Priyanka Shamra is a health and pharma journalist with nearly nine years of field reporting experience. She is a special correspondent with Mint. Her beat includes covering the Ministry of Health and Department of Pharmaceuticals. She also covers the Ministry of Women and Child Development and the Department of Biotechnology.
Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 05 Aug 2022, 11:29 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App